Vitreo Retinal Consultants of the Palm Beaches, P.A. v. U.S. Department of Health & Human Services, 649 F. App'x 684

Background

VRC (Vitreo Retinal Consultants) administered FDA‑approved Lucentis vials (2.0 mg) and extracted up to three 0.5‑mg doses from a single vial ("multi‑dosing") for Medicare Part B patients in 2007–2008, billing Medicare for each 0.5‑mg dose.
Medicare reimbursement was based on Average Sales Price (ASP) +6% (statutory mechanism), yielding a unit price that treated a single 0.5‑mg dose as carrying the full vial cost when used according to the label.
First Coast and contractor SafeGuard audited VRC, concluded VRC overstated expense, and issued an overpayment determination of about $8.98 million; VRC repaid and sought administrative review.
An ALJ found multi‑dosing violated the Lucentis label and thus was not "safe and effective;" the Medicare Appeals Council affirmed that only the first 0.5‑mg dose per vial (administered consistent with the label) was reasonable and reimbursable.
The district court granted summary judgment for HHS. On appeal, the Eleventh Circuit affirmed, reviewing for substantial evidence and arbitrary/capricious agency action.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Whether Medicare reimbursement must ignore physician expense and pay full statutory rate per 0.5‑mg dose regardless of vial use	VRC: Medicare must pay for any dose deemed reasonable and necessary; reimbursement is not tied to a provider's actual expense (citing Hays)	HHS: Reimbursement may reflect the physician's expense when calculation of unit price already assumed disposal per label; VRC overstated expense by billing three doses from one vial	Held: Secretary permissibly required billing to reflect actual expense; substantial evidence supports that VRC overstated expense
Whether administering >1 dose from a single‑use Lucentis vial was medically reasonable and necessary	VRC: Multi‑dosing was clinically acceptable and widely practiced; CMS guidance even encourages efficient use; analogous drugs are multi‑dosed	HHS: Lucentis label requires single‑eye/single‑vial use; noncompliance with label makes additional doses not "safe and effective" for on‑label use	Held: Agency reasonably determined multi‑dosing violated FDA label and thus second/third doses were not medically reasonable and necessary
Whether the agency’s change or combination of rationales renders the decision arbitrary	VRC: HHS shifted from an "overstated expense" rationale to a medical necessity rationale, making action arbitrary	HHS: Either rationale was raised in the record; agency may change position with adequate explanation	Held: No arbitrary change; court addressed both rationales and found them lawful
Whether VRC is entitled to non‑liability or waiver for overpayment (good faith / without fault)	VRC: Could not reasonably have known multi‑dosing would be unpaid; acted in good faith; CMS materials suggest permissive multi‑dosing	HHS: Local Coverage Determination and label provided notice; VRC lacked reasonable basis to assume full payment; not "without fault" for waiver	Held: VRC could reasonably have known reimbursement limited to vials purchased; not entitled to non‑liability or waiver

Key Cases Cited

Heckler v. Ringer, 466 U.S. 602 (Medicare administration and Secretary’s authority to determine coverage)
Bowen v. Georgetown Univ. Hosp., 488 U.S. 204 (Medicare reimburses providers for expenses incurred)
FCC v. Fox Television Stations, Inc., 556 U.S. 502 (agency may change positions if adequately justified)
Nat’l Cable & Telecomms. Ass’n v. Brand X Internet Servs., 545 U.S. 967 (agency inconsistency not automatically fatal to deference)
Hays v. Sebelius, 589 F.3d 1279 (D.C. Cir.) (addressing Medicare payment and least‑cost‑alternative argument)
Wilson v. Barnhart, 284 F.3d 1219 (review standard—substantial evidence for Secretary’s factual findings)